You might be terrified to leave your house lest you catch the Ebola from a male stripper or two, but there are a few health care lobbyists in Washington who couldn’t be more pleased that Americans are shivering at the thought of a disease that has killed less people than have been married to Kim Kardashian.
According to a recent study by the Center for Responsive Politics, health-related lobbying has, in some cases, doubled in just the last few weeks, especially for companies that have Ebola-related treatments in the experimental phases (as if you thought only the government was responsible for developing an emergency Ebola vaccine) and who specialize in infectious disease response.
One such company who doubled the amount they spent on lobbying is Sarepta Therapeutics. Sarepta Therapeutics has been pushing its experimental Ebola treatment AVI-7537 for some time now. In the past, the group has never spent more than $40,000 annually on their lobbying tab. Now,in the third quarter alone, the company has poured $80,000 into lobbying efforts.
Another company, BioCryst Pharmaceuticals, has lobbied exclusively on Ebola for the first time ever in the third quarter — spending $60,000 on “Ebola response.” BioCryst also received $2.4 million from the National Institute of Allergy and Infectious Diseases this past August. After receiving the government funding, the company announced its plan of testing its antiviral in primates for use against Ebola.
A third company, biotech firm Hemispherx BioPharma, received a major boost when the U.S. Army Medical Research Institute of Infectious Diseases agreed to work with the company in testing its experimental drug called Alferon.
America, even though you can’t rest easy after knowing that Ebola will make you bleed out of your eyes and can cause harmful explosive diarrhea, you can at least rest easy knowing that no lobbyists are going to starve in this brutal DC winter.